Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Thursday

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) will be posting its quarterly earnings results after the market closes on Thursday, May 11th. Analysts expect Cyclacel Pharmaceuticals to post earnings of ($0.68) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) last posted its quarterly earnings results on Monday, March 6th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.12). On average, analysts expect Cyclacel Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cyclacel Pharmaceuticals Stock Performance

NASDAQ CYCC opened at $0.57 on Wednesday. The company has a market capitalization of $7.12 million, a P/E ratio of -0.30 and a beta of 1.11. Cyclacel Pharmaceuticals has a one year low of $0.50 and a one year high of $2.41. The stock has a 50 day moving average price of $0.62 and a 200-day moving average price of $0.82.

Hedge Funds Weigh In On Cyclacel Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in shares of Cyclacel Pharmaceuticals in the 2nd quarter valued at about $33,000. HRT Financial LP acquired a new stake in shares of Cyclacel Pharmaceuticals in the 4th quarter valued at about $27,000. Renaissance Technologies LLC acquired a new stake in Cyclacel Pharmaceuticals during the 2nd quarter worth approximately $68,000. Two Sigma Investments LP acquired a new stake in Cyclacel Pharmaceuticals during the 3rd quarter worth approximately $98,000. Finally, Millennium Management LLC acquired a new stake in Cyclacel Pharmaceuticals during the 2nd quarter worth approximately $113,000. Institutional investors and hedge funds own 23.77% of the company’s stock.

Wall Street Analysts Forecast Growth

CYCC has been the topic of several recent research reports. StockNews.com began coverage on Cyclacel Pharmaceuticals in a report on Monday. They set a “sell” rating on the stock. Oppenheimer dropped their price target on Cyclacel Pharmaceuticals from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 7th.

Cyclacel Pharmaceuticals Company Profile

(Get Rating)

Cyclacel Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.